MedTrace Logo

Benefits of Coding Training on Young Adults With Developmental Disabilities

NCT05132491 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2026-02-25

No results posted yet for this study

Summary

The purpose of the present study is to develop and evaluate the Technology Early Career Preparation Intervention (TECH-Prep) program with African American high school students with developmental disabilities. Developmental disabilities include conditions such as Autism spectrum disorders, seizure disorders, behavior disorders, brain injury, cerebral palsy, Down syndrome, and fetal alcohol syndrome/effects. This program is designed to increase technology career interests, self-efficacy, outcome expectancy, goal persistence, and increase entrance into post-secondary education or work subsequent to high school completion of African American youth with developmental disabilities.

Conditions

  • Developmental Disability

Interventions

OTHER

TECH-Prep Intervention

Participants in the treatment program will be asked to complete 10 online training modules (1 hour each), attend 5 online motivational speaker forums (1 hour each), and view 5 coding workshops. The activities will be completed over an 8 week period.

Sponsors & Collaborators

  • Virginia Commonwealth University

    collaborator OTHER

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Timothy Tansey, PhD · University of Wisconsin, Madison

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
24 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-23
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05132491 on ClinicalTrials.gov